REGIONAL INCENTIVES, LEGISLATIONS & GOVERNMENT POLICIES

Raising and investing capital in today's environment requires regional knowledge and an individualised approach. Investment options often depends on the development phase of the venture, investees' preferences, and the political and strategic value of the venture and availability of government-led incentives

9.00  Regional roundup: What are some of the key incentives, supporting legislation 
        and government policies related to biotech funding in the biotech hot spots and 
        emerging centres in Asia?      
        Representatives from government authorities or biotech associations from key biotech 
        regional economies in Asia, namely China, India, Singapore, Korea & Taiwan will provide a 
        national perspective on the following:
       • What are the incentives provided by the individual governments to attract investment into 
         their countries i.e. technical/manpower and IP support, designated incubation services and 
         facilities, tax incentives?
      • What are some government-linked funds available for catalysing and financing new ventures 
        and what are the eligibility criteria for these funds?
      Moderator:    
      Sarath Naru, Managing Director
      APIDC-Venture Capital Ltd, India
      Panelists:     
      Yeoh Keat Chuan, Executive Director,  Biomedical Sciences Group
      Economic Development Board, Singapore          
      Ningni Yu, Vice President
      Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co., China     
      Chei-Hsiang Chen, Director, Biotechnology and Pharmaceutical Industries Program Office, 
      Ministry of Economic Affairs, Taiwan   
      Anna Lavelle, Chief Executive Officer
      AusBiotech Ltd, Australia 

10.30  Morning refreshments & showcase session

INVESTOR-INVESTEE PARTNERSHIPS

The success of a new venture often depends on the relationship and level of synergy built between the founders & management of the company and the investor/ strategic partner and is essential for the long term success of biotech ventures in today's competitive and market-driven environment.

11.00  Case Study/ Panel Discussion: "The Amaranth story¡±        
         The innovator, co-investors and founding management of Amaranth Medical will share their 
         perspectives on the successful development of this multi-national biomedical venture
         • Founding a company based on university technology from Singapore 
         • Obtaining initial seed financing
         • Obtaining U.S. venture capital financing
         • Operating a multi-national start-up
         Moderator: 
         Fred M. Schwarzer, Managing Partner
         Charter Life Sciences, USA 
         Panelists: 
         Freddy Y. C. Boey, Professor & Chair, School of Materials Science and Engineering
         Nanyang Technological University, Singapore  
         Guy Heathers, Former Chief Executive Officer
         Amaranth Medical Pte Ltd, Singapore      
         Lawrence Chin, Director of Investments
         Bio*One Capital, Singapore

11.35  Case Study: Arthritis: The Trillion Dollar Dilemma – Problems & Opportunities  
         • The world's aging but active population demands more and better total technology 
            solutions
          • More trained surgeons, early recognition, prevention and treatment of bones & joints
          • The rise of Small Bone Innovations Inc.(SBI) in meeting unmet patient and surgeons needs
          • Adapting the SBI model to Asia-PAC regional market and regulatory demands     
          Anthony G. Viscogliosi, Principal
          Viscogliosi Bros. LLC, USA & 
          Chairman & Chief Executive Officer, Small Bone Innovations, Inc., USA

CAPITAL RAISING STRATEGY AND CHALLENGES

12.00  VC's perspective on how to successfully form a relationship with US venture 
          firms 
          • Is a US VC the right financing source? 
          • Prospective investor selection
             - Do's and don'ts in identifying, contacting, and selecting the ¡®right' US VC
         • Relationship expectations
            - What to expect in deal terms, syndication
            - What to expect post investment – value adding
         • Case studies and lessons learnt from experience with 2 portfolio companies from UK and 
            Israel
         Suzette Dutch, Managing Partner
         Triathlon Medical Ventures, USA

12.15  Panel Discussion: ¡°Horses for Courses¡±: Match making investors to investees 
          Seasoned VCs specialising in the life sciences sector will share valuable tips on the do's and 
          don't of fund raising for biomedical ventures and how to select the right partner to match 
          specific needs. Great opportunity to hear it straight from the horse's mouth.
          Moderator:       
          Suzette Dutch, Managing Partner
          Triathlon Medical Ventures, USA      
          Panelists:  
          Elliot Parks, Managing Director
          Hamilton BioVentures, USA  
          Fred M. Schwarzer, Managing Partner
          Charter Life Sciences, USA   
          Anthony G. Viscogliosi, Principal
          Viscogliosi Bros. LLC, USA   
          Hui Hsing Ma, Venture Partner
          TVM Capital, Germany  

12.45  Networking Luncheon & showcase session

MANAGING RISK in FINANCING THE DEAL

14.00  Managing risk while investing in early stage biomedical companies          
          • Due diligence prior to investing
          • Managing technical, clinical, and regulatory risks
          • Solving the management challenges along the way
          • Sourcing additional follow-on capital
          Elliot Parks, Managing Director
          Hamilton BioVentures, USA

14.30   Valuation in life sciences: How to put a value on license contracts and biomedial 
           companies?   
           • Methods: DCF, rNPV, Real Options, IRR, Simulations
           • Understanding price vs. value
           • License deals: Valuation for structuring an comparing term sheets
           • Biomedical companies: Building a framework for firm valuation
           Boris Bogdan, Partner
           Avance, Switzerland

15.00  Afternoon refreshments & showcase session

15.30  Small group interactive roundtable discussions  
          The following roundtables will bring together investors and potential investees to discuss the 
          financing of specific biomedical & healthcare sectors, share common experiences and 
          explore partnership opportunities.
          A) Financing medical devices and in vitro diagnostics  
          Moderator: 
          Douglas Schein, CEO
          BOOST Venture Creation, Singapore   
          B) Financing stem cell and regenerative medicine therapeutics
          Moderator:     
          Gregory A. Bonfiglio, Managing Partner, Proteus Venture Partners, USA
          C) Financing drug discovery and development
          Moderator: 
          Anthony Bishop, Director
          Chakra Biotech Pte Ltd & Project Manager, Merlion Pharmaceuticals, Singapore          
          D) Financing consumer healthcare, herbals, traditional medicines
          E) Financing the establishment or expansion of biologics and  pharmaceuticals     
             manufacturing in Asia

17.00  Chairman's closing remarks

17.15  Close of conference